MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cetuximab

产品活性：Cetuximab (C225) 是一种人源 IgG1 单克隆抗体，能够抑制 EGFR，SPR 方法测得 Cetuximab 对 EGFR 的 K_d 值为 0.201 nM；Cetuximab 具有高效的抗肿瘤作用。

研究领域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK

作用靶点：EGFR

In Vitro: Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a K_d of 0.147 nM for EGFR in fixed A431 cells by ELISA. Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G₀/G₁ arrest, induces apoptosis, and reduces Rb, p27^KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells.

In Vivo: Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts.

相关产品：Osimertinib  |  Gefitinib  |  Trastuzumab  |  Erlotinib  |  Afatinib  |  AG490  |  Lapatinib  |  Neratinib  |  Tucatinib  |  Genistein  |  AG-1478  |  Mobocertinib  |  Dacomitinib  |  Pertuzumab  |  Trastuzumab deruxtecan (solution)  |  Gefitinib-based PROTAC 3  |  Trastuzumab emtansine  |  Pyrotinib  |  Sapitinib  |  CUDC-101  |  Tuxobertinib  |  Mubritinib  |  NSC 228155  |  BI-4020  |  Pelitinib  |  TAS6417

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。